ROMK inhibitor - Bristol-Myers Squibb
Latest Information Update: 28 Jun 2024
At a glance
- Originator Bristol-Myers Squibb
- Class Heart failure therapies
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Heart-failure in USA
- 20 May 2021 Bristol Myers Squibb has patent protection for substituted bicycle heterocyclic derivatives useful as romk channel inhibitors in the US
- 20 May 2021 Phase-I clinical trials in Heart failure in USA (unspecified route) (Bristol-Myers Squibb pipeline, May 2021)